Search 

Global Clinical Trials (GCT) is a premium contract-research organization (CRO) that offers support for the clinical Phase I-IV studies as well as post-marketing activities to Big Pharma, small and medium-sized biotech enterprises, groups and funds, as well as large universities and institutions. Headquartered in Princeton, USA, GCT offers both local and global support through 10 own operational offices in Bulgaria, Czech Republic, Georgia, Hungary, India, Kazakhstan, Latvia, Lithuania, Estonia, Moldova, Poland, Romania, Russia, Slovakia, Ukraine.
GCT team, that now consists of over 100 full-time clinical research professionals, gives individualized attention to each project and provides full range of services following the latest GCP, EMA and FDA guidelines at every stage of product development path. Our monitors and project managers are all certified clinicians experienced in GCP clinical research. Our experience, competent staff, close contact with the KOLs and the immense enrollment potential of the covered region ensure fast study start-up and compliance with the set timelines.
GCT owns 400 sq.m. (4300 ft2) Drug Storage and Distribution facility in St. Petersburg, Russia. It is fully equipped, disaster protected and has multiple modes of storage (ambient, climate controlled, refrigerated, frozen). High standards of work and client satisfaction are proved by the fact that more than 80% of the business come from repeat clients.
Since 2006 GCT is also an Exclusive Partner of “The White Nights” International ophthalmology congress in Russia.

Golden State Green World LLC, is a CBG Hemp Cultivator, located in Riverside County, California. Our team has ten years of extensive greenhouse design and a diverse growing experience. We apply our grow methodologies and eco-agricultural knowledge to supply the global market with high quality, contaminant-free, organic CBG enriched hemp products. Our vision is to become a global distributor of organic CBG infused products that will provided medical and therapeutically benefits to the end user.

HebeCell was founded in 2016 by industry leading inventors in developing the manufacturing platform of hematopoietic cells from human pluripotent stem cells (PSCs). Their first-in-class proprietary 3D manufacturing platform for human iPS-NK cells is feeder-free, designed specifically for single-use-bioreactor at industrial scale. HebeCell’s platform will accelerate the application of PSCs as a viable source of immune cells in the next generation of immune cell therapies for immune-Oncology, autoimmune and infectious diseases.

Dr. John Lu is the President and CEO of HebeCell. Before establishing HebeCell, John was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which in 2016 was acquired by Astellas, the second-largest pharmaceutical company in Japan. John is an expert in stem cell biology and regenerative medicine with 20 years of experience in the field.

Dr. Allen Feng is the Chief Scientific Officer of the HebeCell Corp. Prior to establishing HebeCell, he was the Director of Cell Biology of Semma Therapeutics, which was acquired by Vertex Pharmaceuticals in 2019. Prior to Semma, Allen worked as R&D Head of Stem Cell Bioprocessing Group at EMD Millipore, and also served as Director and Senior Scientist at Advanced Cell Technology /Ocata Therapeutics.

Helsinn is a privately-owned Swiss Pharma Company which, since 1976, has been improving the lives of patients, guided by core family values of respect, integrity and quality. The Group has an extensive portfolio of marketed innovative cancer and rare disease therapies, a robust drug development pipeline and ambitions to further accelerate its growth through in-licensing and acquisition to address unmet medical needs. Helsinn operates a unique integrated licensing business model, achieving success with over 80 long-standing partners in 190 countries, who share our values. The Group’s pharmaceutical business, (Helsinn Healthcare) is headquartered in Lugano, Switzerland with operating subsidiaries in the U.S. (Helsinn Therapeutics US) and China (Helsinn Pharmaceuticals China) which market the Group’s products directly in these countries. The Group has additional operating subsidiaries in Switzerland (Helsinn Advanced Synthesis, an active pharmaceutical ingredient manufacturer) and Ireland (Helsinn Birex Pharmaceuticals, a drug product manufacturer). Helsinn Investment Fund was created to enhance the future of healthcare by providing funding and strategic support to innovative companies.

When your clinical trial has to Overachieve in Central and Eastern Europe, HungaroTrial is here to help. Providing services for Phase 1 through Phase 4 clinical trials in Hungary, Czech Republic, Slovakia, Romania, Serbia, Croatia, Bulgaria, Bosnia, Poland, Ukraine, Belgium and Russia, HungaroTrial is the CEE region’s leading independent CRO.

To Overachieve, your clinical trial needs the best minds from beginning to end. That’s why Hungarotrial’s full-time staff includes 12 MDs of various specialties,more than any other independent CRO in the region. And you can be assured that our experienced team has built strong relationships with the most respected Key Opinion Leaders in CEE.

Our staff’s broad medical experience means that your clinical study benefits from diverse skills and synergistic teamwork. Over the past 18 years, HungaroTrial has become well known not just for this broad expertise, but also for our deep experience in Oncology, Rheumatology, Cardiovascular diseases, PAO, CNS and some other focus therapeutic areas.

We are an information-based consulting, integration and IT outsourcing service entity committed to providing premium strategic marketing, financial and operational management solutions for healthcare, pharmaceutical and other life science organisations.

ImmunoBiochem has pioneered a proprietary technology to address the challenges of cancer heterogeneity and tumor penetration by biologics in solid tumors with its tumor microenvironment-targeted potentiated antibodies. ImmunoBiochem's biologics are aimed at targets amplified in the secretomes of cancer cells that enable selective and efficacious delivery of payloads in tumor cells, immune cells and tumor-supporting stroma within the tumor microenvironment. ImmunoBiochem is able to deliver novel immunomodulatory payloads to a variety of cell types within the tumor in a highly selective fashion, pioneering a next-generation strategy for the delivery of innate immune system modulators.

Incuron is a private clinical-stage company that develops a novel class of synthetic small molecules, Curaxins, with a unique multi-targeted mechanism of antitumor activity. These chromatin damaging agents interfere with histone/DNA binding causing decondensation of chromatin in tumor cells, functional inactivation of histone chaperone FACT, and simultaneous effect on a set of universal previously undruggable targets, leading to inhibition of pro-cancer transcriptional factors, MYC, NF-kB, HIF1a, and HSF-1, and activation of the tumor suppressor p53, as well as induction of type I interferon response.
Key advantages of curaxins based on current preclinical and early clinical data include:
- novel mechanism of action that would bring the additional treatment option for advanced and relapsed tumors, as well as potential to overcome resistance to previous treatments;
- favorable pharmacology and manageable safety profiles;
- low potential for serious drug-drug interactions providing opportunities for combinatorial therapeutic regimens;
- broad activity in different tumor types that may open wider market opportunities;
- focused phase 2 clinical study program can establish faster clinical proof of concept and build toward accelerated regulatory approval.
Incuron owns a worldwide patent portfolio, including the composition of matter and therapeutic uses of the compounds.

iNNOGING Medical - Remote and offline ultrasound image analysis solution

Ultrasound is a real-time examination and very much operator dependent.
Majority of ultrasound scans are done by technicians and afterwards diagnosed off-line by the expert without the presence of the patient. A major drawback is that the radiologist who determines the diagnoses is not the person who performs the ultrasound scan; hence this workflow might lead to errors and worse to misdiagnoses.
iNNOGING is developing a technology that will provide the radiologists a remote and off-line tool to inspect areas of interest, based on recorded ultrasound scans. Allowing navigation like in real time as if the patient is there with the doctor, while all possible information (any plane) of an organ is visible, even information that was not presented in the original scan.

In addition to the above, we have recently launched an affordable SaaS based Ultrasound Simulator.